Gene therapies are still hampered by substantial delays between approval and launch

Forbes

3 May 2023 - Gene therapies hold promise for treating a wide range of diseases. Innovative companies such as bluebird bio and BioMarin are at the forefront of clinical development. 

Yet, firms face numerous challenges, in all phases, from pre-clinical through Phase 3.

Read Forbes article

Michael Wonder

Posted by:

Michael Wonder